
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2715038/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology, 2013, 31, 344-350.	1.6	1,003
2	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
3	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 2021, 18, 170-186.	27.6	826
4	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology, The, 2017, 18, e315-e329.	10.7	816
5	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	27.8	761
6	Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology. Cancer Research, 2009, 69, 9065-9072.	0.9	575
7	Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nature Genetics, 2011, 43, 1256-1261.	21.4	488
8	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	27.8	320
9	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
10	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
11	The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro-Oncology, 2018, 20, 103-112.	1.2	220
12	Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. Lancet Oncology, The, 2011, 12, 83-91.	10.7	188
13	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
14	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro-Oncology, 2016, 18, 388-400.	1.2	143
15	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-Oncology, 2020, 22, 515-523.	1.2	140
16	Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro-Oncology, 2015, 17, 935-941.	1.2	136
17	IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Annals of Neurology, 2011, 69, 455-463.	5.3	132
18	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq0	0 0 rgBT 10.7	/Overlock 10 132

Oncology, The, 2021, 22, 813-823.

#	Article	IF	CITATIONS
19	Recurrent noncoding U1ÂsnRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature, 2019, 574, 707-711.	27.8	129
20	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro-Oncology, 2020, 22, 684-693.	1.2	126
21	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology, 2018, 20, 873-884.	1.2	119
22	A Hypermethylated Phenotype Is a Better Predictor of Survival than <i>MGMT</i> Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951. Clinical Cancer Research, 2011, 17, 7148-7155.	7.0	107
23	<i>MGMT</i> -STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951. Clinical Cancer Research, 2013, 19, 5513-5522.	7.0	106
24	Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. Cancers, 2021, 13, 47.	3.7	106
25	Gene Expression Profiles Associated with Treatment Response in Oligodendrogliomas. Cancer Research, 2005, 65, 11335-11344.	0.9	102
26	Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951. Journal of Clinical Oncology, 2013, 31, 328-336.	1.6	99
27	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. Cancer Research, 2016, 76, 525-534.	0.9	93
28	Segregation of non-p.R132H mutations in <i>IDH1</i> in distinct molecular subtypes of glioma. Human Mutation, 2010, 31, E1186-E1199.	2.5	90
29	Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathologica, 2017, 134, 957-959.	7.7	87
30	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
31	Molecular Evolution of <i>IDH</i> Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. Journal of Clinical Oncology, 2020, 38, 81-99.	1.6	84
32	Identification of Differentially Regulated Splice Variants and Novel Exons in Glial Brain Tumors Using Exon Expression Arrays. Cancer Research, 2007, 67, 5635-5642.	0.9	81
33	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncology, The, 2018, 19, 1170-1179.	10.7	80
34	Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors. Advances in Anatomic Pathology, 2013, 20, 32-38.	4.3	73
35	Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm. Clinical Cancer Research, 2019, 25, 7455-7462.	7.0	70
36	Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. Cancers, 2020, 12, 751.	3.7	66

PIM J FRENCH

#	Article	IF	CITATIONS
37	Detailed Characterization of Alterations of Chromosomes 7, 9, and 10 in Glioblastomas as Assessed by Single-Nucleotide Polymorphism Arrays. Journal of Molecular Diagnostics, 2011, 13, 634-647.	2.8	55
38	Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix–associated gene modules. Neuro-Oncology, 2013, 15, 1684-1695.	1.2	55
39	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
40	Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens. Scientific Reports, 2019, 9, 14643.	3.3	44
41	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathologica Communications, 2015, 3, 88.	5.2	42
42	Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. Acta Neuropathologica Communications, 2018, 6, 126.	5.2	38
43	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro-Oncology, 2021, 23, 1547-1559.	1.2	34
44	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	7.7	34
45	Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning. Neuro-Oncology, 2023, 25, 279-289.	1.2	34
46	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	7.7	32
47	Subgroup-specific alternative splicing in medulloblastoma. Acta Neuropathologica, 2012, 123, 485-499.	7.7	28
48	Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. European Journal of Cancer, 2018, 94, 168-178.	2.8	28
49	Molecular subtypes of glioma identified by genomeâ€wide methylation profiling. Genes Chromosomes and Cancer, 2013, 52, 665-674.	2.8	27
50	TRiC controls transcription resumption after UV damage by regulating Cockayne syndrome protein A. Nature Communications, 2018, 9, 1040.	12.8	27
51	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 2022, 28, 2527-2535.	7.0	27
52	Integrated genomic profiling identifies candidate genes implicated in gliomaâ€genesis and a novel <i>LEO1</i> â€ <i>SLC12A1</i> fusion gene. Genes Chromosomes and Cancer, 2010, 49, 509-517.	2.8	25
53	Genetic Alterations in Glioma. Cancers, 2011, 3, 1129-1140.	3.7	24
54	Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. Journal of Neuro-Oncology, 2018, 139, 349-357.	2.9	24

#	Article	IF	CITATIONS
55	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. Journal of Neuro-Oncology, 2019, 144, 205-210.	2.9	24
56	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
57	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 2022, 40, 2539-2545.	1.6	23
58	Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-Oncology, 2011, 103, 221-230.	2.9	21
59	Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation. European Journal of Cancer, 2015, 51, 893-903.	2.8	21
60	Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. Journal of Clinical Oncology, 2015, 33, 1943-1950.	1.6	21
61	Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. Blood Advances, 2021, 5, 2687-2700.	5.2	21
62	Defining EGFR amplification status for clinical trial inclusion. Neuro-Oncology, 2019, 21, 1263-1272.	1.2	20
63	A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. Molecular Oncology, 2016, 10, 1296-1304.	4.6	19
64	Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection. PLoS ONE, 2017, 12, e0179920.	2.5	19
65	Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma. Cancers, 2020, 12, 3589.	3.7	19
66	Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas. Cancers, 2018, 10, 489.	3.7	18
67	Human branching cholangiocyte organoids recapitulate functional bile duct formation. Cell Stem Cell, 2022, 29, 776-794.e13.	11.1	17
68	SMARCAD1-mediated active replication fork stability maintains genome integrity. Science Advances, 2021, 7, .	10.3	15
69	A bypass mechanism of abirateroneâ€resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. Prostate, 2019, 79, 937-948.	2.3	14
70	Tumor-specific mutations in low-frequency genes affect their functional properties. Journal of Neuro-Oncology, 2015, 122, 461-470.	2.9	13
71	The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma. Data in Brief, 2021, 37, 107191.	1.0	13
72	Absence of Common Somatic Alterations in Genes on 1p and 19q in Oligodendrogliomas. PLoS ONE, 2011, 6, e22000.	2.5	13

#	Article	IF	CITATIONS
73	Exon Expression Arrays as a Tool to Identify New Cancer Genes. PLoS ONE, 2008, 3, e3007.	2.5	12
74	Structural and Expression Differences Between the Vasculature of Pilocytic Astrocytomas and Glioblastomas. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1171-1181.	1.7	12
75	Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids. Prostate Cancer and Prostatic Diseases, 2023, 26, 293-301.	3.9	12
76	Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients. Journal of Neuro-Oncology, 2019, 144, 79-87.	2.9	11
77	Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures. Neuro-Oncology Advances, 2021, 3, vdab103.	0.7	10
78	Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing. Biomolecules, 2021, 11, 1572.	4.0	10
79	Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNA–minus RNA sequencing data. GigaScience, 2021, 10, .	6.4	10
80	Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups. Neuro-Oncology Advances, 2019, 1, vdz001.	0.7	9
81	EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. Neuro-Oncology Advances, 2020, 2, vdz051.	0.7	9
82	A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?. Cancers, 2020, 12, 3775.	3.7	9
83	Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. Scientific Reports, 2020, 10, 2927.	3.3	8
84	Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion Journal of Clinical Oncology, 2017, 35, 2009-2009.	1.6	8
85	Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors. EBioMedicine, 2020, 56, 102796.	6.1	7
86	The <i>EGFRvIII</i> transcriptome in glioblastoma: A meta-omics analysis. Neuro-Oncology, 2022, 24, 429-441.	1.2	7
87	Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. EBioMedicine, 2021, 73, 103681.	6.1	6
88	The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review. Neuro-Oncology Advances, 2022, 4, .	0.7	6
89	Raman spectroscopy can discriminate distinct glioma subtypes as defined by RNA expression profiling. Journal of Raman Spectroscopy, 2013, 44, 1217-1221.	2.5	5
90	Evidence-based management of adult patients with diffuse glioma – Authors' reply. Lancet Oncology, The, 2017, 18, e430-e431.	10.7	5

#	Article	IF	CITATIONS
91	ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION. Neuro-Oncology, 2019, 21, vi14-vi14.	1.2	5
92	Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles. Oncotarget, 2018, 9, 28083-28102.	1.8	5
93	<i>MGMT</i> promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas. Neuro-Oncology, 2022, 24, 665-667.	1.2	5
94	IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis. PLoS ONE, 2018, 13, e0199737.	2.5	4
95	Landscape of Driver Gene Events, Biomarkers and Druggable Targets Identified by Whole Genome Sequencing of Glioblastomas. Neuro-Oncology Advances, 2022, 4, vdab177.	0.7	3
96	Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. Clinical Cancer Research, 2022, 28, 2440-2448.	7.0	3
97	SURG-05. THE IMPACT OF SURGERY IN MOLECULARLY DEFINED LOW-GRADE GLIOMA: AN INTEGRATED CLINICAL, RADIOLOGICAL AND MOLECULAR ANALYSIS. Neuro-Oncology, 2017, 19, vi236-vi236.	1.2	1
	ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON		

DEPATUXâ€[™] ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE